Watch · Quality 22/100
Simple research view
BIIB · Biogen Inc.
$200.14 latest stored close
Switch to Advanced for indicator panels, raw grades, provenance, drawing tools, and full technical tables.
$BIIB
Biogen Inc.Biogen Inc. is a large-cap Pharmaceuticals: Major company in the Health Technology sector with a market cap of $30B.
Council read · 6 methods
Watch — evidence is building
0 buyable · 5 watch · 1 avoid. Review the observed passes and blockers before reading the chart.
Earnings-risk mode
Pre-earnings setup
Thursday, July 30, 2026
Time not confirmed
No sourced report session or clock time
Ordinary position sizing suppressed.
Earnings are less than three full trading sessions away; treat the gap as event risk, not ordinary stop-distance risk.
Deterministic evidence
BIIB-1.01%
Sector proxy · XLV+0.51%
Broad market · SPY+0.02%
CatalystUnavailable
Stock reactionNegative
Sector reactionSupportive
Opening surgeUnavailable
Event riskEarnings-driven
Price bars, sourced event fields, and benchmark math only. This can adjust displayed short-term conviction; it does not change the stored scanner score or readiness.
AI interpretation (optional)
Ask a Legend to interpret the evidence only after reviewing the deterministic event timing and relative reaction.
Interpret this evidence AI output is commentary, not scanner evidence or a sizing recommendation.BIIB Chart
Interactive price, volume, RS, RSI, and MACD charts are available after sign in.
Setup Quality
B
4/7 signals
Score trend
✓
Stage 2 · Advancing
✗
Power Trend
✗ RS New High
✓ Trend 8/8
✗
No Pattern
✓ CANSLIM 74.1 (B)
✓ Gatekeeper
Base #3 (C)
Technical Analysis Report Card
$BIIB · $200.14 · as of 2026-07-27 · multi-factor read
59
/ 100
Trend · Daily / Weekly / Monthly
Daily
▬ Sideways / consolidating
Weekly
▬ Sideways / consolidating
Monthly
▬ Sideways / consolidating
Moving Averages
50-day$199.34 ↑
100-day$192.30 ↑
200-day$182.18 ↑
Bullish (50 > 200)
RSI (14)
Reading48.7 · Neutral
Neutral — momentum is balanced between buyers and sellers.
MACD (12/26/9)
StateWeakening
Histogram-0.711
Weakening — MACD slipped below its signal line. Histogram expanding.
Bollinger Bands (20,2)
%B / Width34% · 13.4%
Mid-band — no directional band edge in play.
Volume · Buyer vs Seller
Up/Down vol0.7 · Neutral
Rel volume0.6×
Balanced — up/down volume is roughly even; no clear hand. Recent volume is expanding versus its baseline.
Support & Resistance
R · $202.93swing level
R · $205.97swing level
R · $215.79swing level
Price · $200.14now
S · $193.20swing level
S · $185.70swing level
S · $181.24swing level
Fibonacci · Uptrend swing
23.6%$207.67
38.2% ◄ price here$200.21
50.0%$194.18
61.8%$188.15
78.6%$179.57
Retracement support zones measured from the recent swing low up to the high.
The verdict is free. The trade plan is Pro.
Unlock the exact entry, stop-loss, profit target, and reward-to-risk for BIIB — plus the full 495-symbol scanner and Ask-the-Legends chat.
🔒 Start your 7-day free trial →
Above 200-day MA50/200 bullish
Want this read in a legend's voice?
💬 Ask a Legend about BIIB
Generic technical analysis generated mechanically from price & volume — educational research only, not financial advice or a personalized recommendation. Levels are illustrative; confirm on your own chart. New to these terms? →
Legend Verdicts
6 methodology checks
Who would consider this setup, why it qualifies, and what blocks it — calculated from the same deterministic methodology rules used across Legend AI.
Council consensus:
🟡 5 of 6 legends are Watching — building, not yet a confirmed buy.
Watch
Minervini B
Trend-template read: 10/12 pass; wait for the soft misses to improve.
Passing evidence
1.1 Price > 150-day MA AND 200-day MAPrice $200.14, MA150 $188.88, MA200 $182.18
1.2 150-day MA > 200-day MAMA150 $188.88 vs MA200 $182.18
Failing evidence
2. ROE ≥ 17%ROE 7.5%
2. Revenue growth ≥ 20% YoY+2.2% YoY
Avoid
O'Neil D
CANSLIM read: fails L: RS rank ≥ 80 (IBD leadership).
Passing evidence
C: Quarterly EPS acceleration ≥ 25%+79.4% QoQ
N: Near 52-week high or RS line new high8.9% below high | RS line new high: False
Failing evidence
L: RS rank ≥ 80 (IBD leadership)RS rank 71
A: Annual earnings & revenue qualityRev +2.2% | ROE 7.5%
Watch
Weinstein C
Stage-analysis read: Stage 2 is present; 2 supporting checks need improvement.
Passing evidence
Stage 2 (Advancing phase) confirmedStage 2 (Advancing)
Price above 30-week MA (200-day proxy)Price $200.14 vs MA200 $182.18
Failing evidence
Volume expansion above averageVolume ratio 0.60x
Weekly price coiling (Stage 2 consolidation)Tightening weekly range confirms base
Watch
Livermore B
Pivotal-point read: constructive evidence is present, but volume vs average is unresolved.
Passing evidence
Price$200.14
Relative strengthRS 71
Failing evidence
Volume vs average0.60x
Pivotal point cleared on expanding volumeNot confirmed
Watch
Darvas B
Box-theory read: constructive evidence is present, but volume vs average is unresolved.
Passing evidence
Price$200.14
Relative strengthRS 71
Failing evidence
Volume vs average0.60x
Box top broken on heavy volumeNot confirmed
Watch
Wyckoff B
Supply-and-demand read: constructive evidence is present, but volume vs average is unresolved.
Passing evidence
Price$200.14
Relative strengthRS 71
Failing evidence
Volume vs average0.60x
Sign of Strength confirmed on expanding volumePrice hasn't cleared the pivot yet — confirmation pending
Breakout Health
No active breakout tracked — Legend AI monitors daily for pivot-point breaks. What's a breakout?
RS Line vs SPY
52-week relative strength · blue = RS line · dashed = MA50 · dot = NH
▼ Falling
Accumulation / Distribution
last 65 sessions · green = acc on high vol · red = dist on high vol
Net -5
Fundamentals & leadership quality — Minervini SEPA criteria · 4/7 met
B
4/7 SEPA
Separate score from the 8-point Trend Template (8/8): the Trend Template grades the price structure, this grades the company & leadership (earnings, sales, margins, RS rank). A stock can ride a clean trend while its fundamentals lag, so the two often differ by design — they are not the same checklist.
EPS acceleration ≥25% QoQ
+79%
Revenue growth ≥20% YoY
+2%
Gross margin ≥30%
75%
ROE ≥17%
8%
RS rating ≥80 (leadership)
71
Stage 2 uptrend (Weinstein)
Stage 2
Within 25% of 52W high
-8.9%
Method Playbook
📋 Trade it like Livermore
EXACT LEVELS · PRO
Livermore B · Watch — The deterministic methodology check is Watch; wait for the failing or incomplete criteria to improve before the trigger can qualify.
Pivot
Pro levelPublished-method rule: Treat the resistance break as a pivotal point only while the primary trend and relative strength remain aligned.
Evidence: Canonical setup geometry is available with Pro.
Evidence: Canonical setup geometry is available with Pro.
Entry trigger
Pro levelPublished-method rule: Wait for price and volume to confirm the pivotal-point break; anticipation below the line is not confirmation.
Evidence: Canonical setup geometry is available with Pro.
Evidence: Canonical setup geometry is available with Pro.
Initial stop
Pro levelPublished-method rule: Place the initial stop below the pivotal line or the reaction low that would prove the breakout false.
Evidence: Canonical setup geometry is available with Pro.
Evidence: Canonical setup geometry is available with Pro.
Trail
Rule-basedPublished-method rule: Raise protection beneath successive higher reaction lows as the trend advances; never move a protective line farther away.
Evidence: Planned management rule; no stored stop or broker order is changed automatically.
Evidence: Planned management rule; no stored stop or broker order is changed automatically.
Exit / invalidation
Pro levelPublished-method rule: Exit when price fails the pivotal line, breaks the latest meaningful reaction low, or shows abnormal reversal action.
Evidence: Canonical setup geometry is available with Pro.
Evidence: Canonical setup geometry is available with Pro.
Deterministic educational plan, not a recommendation. No order or stop is changed automatically. Method and sources →
The published-method workflow is public. Unlock exact pivot, entry, stop, target, and sizing with Pro →
Forming Patterns (predictive — not confirmed)
Head & Shoulders
bearish
forming
75%
built
Possible head & shoulders top — not confirmed. Watch for a daily close below ~186.33 (neckline) to confirm, with measured-move risk toward ~152.94. A push back above 215.79 weakens the pattern; reclaiming 219.72 invalidates it.
Confirms below
186.33
Invalidates at
219.72
Left Shoulder
205.97
Head
219.72
Right Shoulder
215.79
Neckline
186.33
Target
152.94
LS 205.97 / head 219.72 / RS 215.79, neckline ~186.33, vol_fading=yes
Predictive pattern recognition is educational — most forming structures never confirm. Wait for the confirmation level before treating this as a setup.
Pattern Analysis
Inverse Head & Shoulders
⚠ 3rd-stage base
76.1
score
RS Score
71
Trend
8/8 ✓
CANSLIM
74.1* (B)
left shoulder: 180.33
head: 168.64
right shoulder: 179.15
shoulder symmetry: 0.007
prior decline: 0.167
sessions since breakout: 60
breakout volume ratio: 0.868
retest: ✓
validation reason: valid inverse head-and-shoulders
multi tf evaluated: ✓
multi tf reason: weekly trend template 8/8 confirmed
Why This Setup?
Inverse Head & Shoulders
Inverse H&S breakout: LS 180.33, head 168.64, RS 179.15, neckline 194.48, breakout 60 bars ago, vol 0.87x | Strong trend (8/8) | Good RS (71) | High-confidence pattern (81%) | Stage 2 | Readiness 70/100 (watch) | CANSLIM 74.1 (B) | ⚠ 3rd-stage base
The Universal Edge Check
The panel is uneasy
Too many universals unmet — this leans closer to a guess than a trade.
1/7
universals met
- In a confirmed uptrend Stage 2 · Trend 8/8
- Risk is defined No stop — undefined risk
- Asymmetric reward No target set
- Not chasing (in range) Pivot distance unknown
- Volume confirms 0.6× average — light
- Clear of earnings in 2 days — event risk
- A relative-strength leader RS 74 — middling
Minervini Trend Template
8/8Grades the price structure — moving-average stacking, distance from the 52-week high/low, and relative strength above the ≥70 uptrend bar. This is the technical trend check; the company's fundamentals and ≥80 RS leadership are scored separately in the Grade Card.
Price above SMA 150 & 200
$200.14 vs SMA150 $188.88 / SMA200 $182.18
SMA 150 above SMA 200
SMA150 $188.88 vs SMA200 $182.18
SMA 200 trending up
Slope +5.94 over 20 days
SMA 50 above SMA 150 & 200
SMA50 $199.34
Price above SMA 50
$200.14 vs SMA50 $199.34
30%+ above 52W low
+60.7% from $124.56
Within 25% of 52W high
-8.9% from $219.72
RS score above 70
RS 71
Fundamentals
52W Range
79%
Mkt Cap SEC
29.5B
EPS QoQ
+79%
Rev YoY
+2%
ROE
8%
Gross Margin
75%
D/E
0.34
EPS TTM
$8.79
P/E TTM
22.8x
Float
148M
Insider
No Buy
Company
Legend AI snapshot
Biogen Inc.
$200.14latest close
$29.5Bmarket cap
74RS rank
76setup score
CANSLIM — current EPS, annual EPS, new highs, supply, leader RS, inst. sponsorship, market
B
74.1* CANSLIM
* disqualified on M
C · Curr. EPS
100
A · Annual EPS
62
N · New Highs
100
S · Supply/Demand
55
L · Leader RS
71
I · Inst. Spons.
100
M · Market
30
Weekly Context
Multi-timeframe signals from weekly barsW. Trend
8/8
W. RS
80
W. Support
$168.64
W. Resist
$219.72
Weekly Structure
Trend
Neutral
Tight Weeks
0
Confirmation
Neutral
Scan History
20× streakJul 28
Inverse Head & Shoulders
✓ Gate
76
Jul 28
Inverse Head & Shoulders
✓ Gate
76
Jul 27
Inverse Head & Shoulders
✓ Gate
77
0.0%
Jul 27
Inverse Head & Shoulders
✓ Gate
76
0.0%
Jul 24
Inverse Head & Shoulders
✓ Gate
76
-1.0%
Jul 24
Inverse Head & Shoulders
✓ Gate
76
-1.0%
Get the full picture on BIIB
Pro members see entry/stop/target levels, R:R ratios, intraday alerts, and every setup detected across 495+ symbols daily.
Start 7-Day Free Trial